Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12716163 | 0.84 | TXNRD1 (0.52) | TXNRD1KMT2AHTTELANEHPGD | |
| SCHEMBL4740792 | 0.82 | TXNRD1 (0.56) | TXNRD1KMT2AHTTELANEHPGD | |
| SCHEMBL1616096 | 0.75 | TXNRD1 (0.53) | TXNRD1HTTLMNA | |
| SCHEMBL14511071 | 0.74 | TXNRD1 (0.45) | TXNRD1 | |
| SCHEMBL12716307 | 0.72 | TXNRD1 (0.50) | TXNRD1 | |
| SCHEMBL14511070 | 0.70 | CTSB (0.48) | TXNRD1 | |
| SCHEMBL16638891 | 0.70 | TXNRD1 (0.67) | TXNRD1KMT2AHTTELANEHPGD | |
| SCHEMBL1998230 | 0.70 | CA12 (0.59) | TXNRD1ELANEHPGDKDM4EL3MBTL1 | |
| SCHEMBL14511068 | 0.68 | TXNRD1 (0.46) | TXNRD1ALDH1A1THRB | |
| SCHEMBL1994212 | 0.67 | CA12 (0.55) | TXNRD1ELANEHPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | ACTIVX BIOSCIENCES, INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | DNPEP, CTRL, ARSA | TXNRD1 2552/4885KMT2A 3310/4885HTT 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.